PHOSPHODIESTERASE-4 INHIBITION REDUCES PROTEOLYSIS AND ATROGENES EXPRESSION IN RAT SKELETAL MUSCLES

被引:23
|
作者
Lira, Eduardo C. [1 ]
Goncalves, Dawit A. P. [1 ]
Parreiras-E-Silva, Lucas T. [2 ]
Zanon, Neusa M. [1 ]
Kettelhut, Isis C. [2 ]
Navegantes, Luiz C. C. [1 ]
机构
[1] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Physiol, BR-14049900 Ribeirao Preto, SP, Brazil
[2] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Biochem & Immunol, BR-14049900 Ribeirao Preto, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
atrogenes; autophagy; cAMP; phosphodiesterase; proteolysis; PROTEASOME-DEPENDENT PROTEOLYSIS; PKB PHOSPHORYLATION; ATROPHY INVOLVE; PROTEIN-KINASE; INSULIN; CAMP; ACTIVATION; EPAC; MICRODIALYSIS; STIMULATION;
D O I
10.1002/mus.22066
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Phosphodiesterase (PDE) inhibition reduces skeletal muscle atrophy, but the underlying molecular mechanism remains unclear. We used microdialysis to investigate the effects of different PDE inhibitors on interstitial tyrosine concentration as well as proteolytic activity and atrogenes expression in isolated rat muscle. Rolipram, a PDE-4-selective inhibitor, reduced the interstitial tyrosine concentration and rates of muscle protein degradation. The rolipram-induced muscle cAMP increase was accompanied by a decrease in ubiquitin proteasome system (UPS) activity and atrogin-1 mRNA, a ubiquitin-ligase involved in muscle atrophy. This effect was not associated with Akt phosphorylation but was partially blocked by a protein kinase A inhibitor. Fasting increased atrogin-1, MuRF-1 and LC3b expression, and these effects were markedly suppressed by rolipram. Our data suggest that activation of cAMP signaling by PDE-4 blockade leads to inhibition of UPS activity and atrogenes expression independently of Akt. These findings are important for identifying novel approaches to attenuate muscle atrophy. Muscle Nerve 44: 371-381, 2011
引用
收藏
页码:371 / 381
页数:11
相关论文
共 50 条
  • [1] ROLIPRAM INHIBITION OF PHOSPHODIESTERASE-4 ACTIVATION
    DISANTO, ME
    HEASLIP, RJ
    EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1995, 290 (02): : 169 - 172
  • [2] Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy
    Hinkle, RT
    Dolan, E
    Cody, DB
    Bauer, MB
    Isfort, RJ
    MUSCLE & NERVE, 2005, 32 (06) : 775 - 781
  • [3] The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia
    Barreiro, Esther
    Puig-Vilanova, Ester
    Salazar-Degracia, Anna
    Pascual-Guardia, Sergi
    Casadevall, Carme
    Gea, Joaquim
    JOURNAL OF APPLIED PHYSIOLOGY, 2018, 125 (02) : 287 - 303
  • [4] Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases
    Picchianti-Diamanti, Andrea
    Spinelli, Francesca Romana
    Rosado, Maria Manuela
    Conti, Fabrizio
    Lagana, Bruno
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (05) : 1 - 14
  • [5] THE NOVEL DISTRIBUTION OF PHOSPHODIESTERASE-4 SUBTYPES WITHIN THE RAT RETINA
    Whitaker, C. M.
    Cooper, N. G. F.
    NEUROSCIENCE, 2009, 163 (04) : 1277 - 1291
  • [6] Roflumilast, a phosphodiesterase-4 (PDE4) inhibitor, induces respiratory frequency plasticity that is resistant to inflammation in neonatal rat in vitro preparations
    Johnson, Stephen M.
    Rastas, Jacob P.
    Desai, Pujal S.
    Baker, Tracy L.
    Watters, Jyoti J.
    RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, 2025, 335
  • [7] Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential
    Roy, Dhritiman
    Balasubramanian, Shivaramakrishnan
    Krishnamurthy, Praveen Thaggikuppe
    Sola, Piyong
    Rymbai, Emdormi
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 2023, 43 (06) : 2713 - 2741
  • [8] Phosphodiesterase-4 Inhibition in Parkinson’s Disease: Molecular Insights and Therapeutic Potential
    Dhritiman Roy
    Shivaramakrishnan Balasubramanian
    Praveen Thaggikuppe Krishnamurthy
    Piyong Sola
    Emdormi Rymbai
    Cellular and Molecular Neurobiology, 2023, 43 : 2713 - 2741
  • [9] Inhibition of Uterine Contractility by Thalidomide Analogs via Phosphodiesterase-4 Inhibition and Calcium Entry Blockade
    Fernandez-Martinez, Eduardo
    Ponce-Monter, Hector
    Soria-Jasso, Luis E.
    Ortiz, Mario I.
    Arias-Montano, Jose-Antonio
    Barragan-Ramirez, Guillermo
    Mayen-Garcia, Cynthia
    MOLECULES, 2016, 21 (10)
  • [10] Phosphodiesterase-4 inhibition as a therapeutic approach to treat capillary leakage in systemic inflammation
    Schick, Martin Alexander
    Wunder, Christian
    Wollborn, Jakob
    Roewer, Norbert
    Waschke, Jens
    Germer, Christoph-Thomas
    Schlegel, Nicolas
    JOURNAL OF PHYSIOLOGY-LONDON, 2012, 590 (11): : 2693 - 2708